[Federal Register: October 21, 2005 (Volume 70, Number 203)]
[Notices]
[Page 61293]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr21oc05-93]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Science Board to the Food and Drug Administration; Notice of
Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). The meeting will
be open to the public.
Name of Committee: Science Board to FDA.
General Function of the Committee: The Board shall provide advice
primarily to the agency's Senior Science Advisor and, as needed, to the
Commissioner of Food and Drugs and other appropriate officials on
specific complex and technical issues as well as emerging issues within
the scientific community in industry and academia. Additionally, the
Board will provide advice to the agency on keeping pace with technical
and scientific evolutions in the fields of regulatory science, on
formulating an appropriate research agenda, and on upgrading its
scientific and research facilities to keep pace with these changes. It
will also provide the means for critical review of agency-sponsored
intramural and extramural scientific research programs.
Date and Time: The meeting will be held on November 4, 2005, from
8:30 a.m. to 4 p.m.
Location: Washington Room, Holiday Inn Bethesda, 8120 Wisconsin
Ave., Bethesda, MD.
Contact Person: Jan Johannessen, Office of the Commissioner (HF-
33), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD
20857, 301-827-6687, jjohannessen@fda.gov, or FDA Advisory Committee
Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC
area), code 3014512603. Please call the Information Line for up-to-date
information on this meeting.
Agenda: The Science Board will hear about and discuss the following
topics: (1) An update on activities of the Drug Safety Oversight Board,
(2) the agency's Bioresearch Monitoring Initiative, and (3) the Board's
science peer review activities, including presentation of the Board's
peer review of the Office of Regulatory Affairs' pesticide monitoring
program.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person by October 28,
2005. Oral presentations from the public will be scheduled between
approximately 12:30 p.m. and 1:30 p.m. Time allotted for each
presentation may be limited. Those desiring to make formal oral
presentations should notify the contact person before October 28, 2005,
and submit a brief statement of the general nature of the evidence or
arguments they wish to present, the names and addresses of proposed
participants, and an indication of the approximate time requested to
make their presentation.
Persons attending FDA's advisory committee meetings are advised
that the agency is not responsible for providing access to electrical
outlets.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
physical disabilities or special needs. If you require special
accommodations due to a disability, please contact Jan Johannessen at
least 7 days in advance of the meeting.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: October 14, 2005.
Jason Brodsky,
Acting Associate Commissioner for External Relations.
[FR Doc. 05-21036 Filed 10-20-05; 8:45 am]
BILLING CODE 4160-01-S